TPMT and NUDT15 Variants Predict Discontinuation of Azathioprine for Myelotoxicity in Patients with Inflammatory Disease: Real‐World Clinical Results-Reference-Cited by-同舟云学术

TPMT and NUDT15 Variants Predict Discontinuation of Azathioprine for Myelotoxicity in Patients with Inflammatory Disease: Real‐World Clinical Results

Published:2021-10-12 Issue:1 Volume:111 Page:263-271
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:en
Short-container-title:Clin Pharma and Therapeutics

Author:

Dickson Alyson L.¹,Daniel Laura L.¹,Zanussi Jacy¹,Dale Plummer W.²,Wei Wei‐Qi³,Liu Ge³,Reese Tyler¹,Anandi Prathima¹,Birdwell Kelly A.¹,Kawai Vivian¹,Cox Nancy J.¹⁴,Dupont William D.²,Hung Adriana M.¹⁵,Feng QiPing¹,Stein C. Michael¹⁶,Chung Cecilia P.¹⁴⁵

Affiliation:

1. Department of Medicine Vanderbilt University Medical Center Nashville Tennessee USA

2. Department of Biostatistics Vanderbilt University Medical Center Nashville Tennessee USA

3. Department of Bioinformatics Vanderbilt University Medical Center Nashville Tennessee USA

4. Vanderbilt Genetics InstituteVanderbilt University School of Medicine Nashville Tennessee USA

5. Tennessee Valley Healthcare System ‐ Nashville Campus Nashville Tennessee USA

6. Department of Pharmacology Vanderbilt University Medical Center Nashville Tennessee USA

Funder

Rheumatology Research Foundation

National Institutes of Health

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpt.2428

Reference41 articles.

1. World Health Organization (WHO).WHO Model List of Essential Medicines (2017). Accessed July 9 2019.

2. New genetic associations in thiopurine-related bone marrow toxicity among inflammatory bowel disease patients

3. IMPDH1 promoter mutations in a patient exhibiting azathioprine resistance

4. Thiopurine pharmacogenomics: association of SNPs with clinical response and functional validation of candidate genes

5. Split-dose administration of thiopurine drugs: a novel and effective strategy for managing preferential 6-MMP metabolism

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Early therapeutic drug monitoring helps to identify inflammatory bowel disease patients with a high risk to fail thiopurine treatment;British Journal of Clinical Pharmacology;2024-08-25

2. The Contribution of Genetic and Epigenetic Factors: An Emerging Concept in the Assessment and Prognosis of Inflammatory Bowel Diseases;International Journal of Molecular Sciences;2024-08-01

3. Landscape of TPMT and NUDT15 Pharmacogenetic Variation in a Cohort of Canadian Pediatric Inflammatory Bowel Disease Patients;Inflammatory Bowel Diseases;2024-05-24

4. Estimation of the benefit from pre‐emptive genotyping based on the nationwide cohort data in South Korea;Clinical and Translational Science;2024-03

5. Prognostic factors for liver, blood and kidney adverse events from glucocorticoid sparing immune-suppressing drugs in immune-mediated inflammatory diseases: a prognostic systematic review;RMD Open;2024-01